The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever

PHASE3CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

April 28, 2025

Study Completion Date

May 29, 2025

Conditions
Dengue FeverDengue Hemorrhagic FeverSevere Dengue
Interventions
DRUG

Ribavirin

Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.

OTHER

Standard Treatment

"The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol."

Trial Locations (4)

09152

Lady Reading Hospital, Peshawar

Unknown

Gandhara Medical Hospital, Peshawar

Medical Complex Swabi, Swābi

Kohat Institute of Medical Science, Kohat

All Listed Sponsors
lead

Khyber Medical University Peshawar

OTHER

NCT06744777 - The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever | Biotech Hunter | Biotech Hunter